“FDA-approved carbonic anhydrase inhibitors reduce Amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness”

“FDA-approved carbonic anhydrase inhibitors reduce Amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness” is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2022). On theSindex it has a DataRank of 0. It has been cited 1 time.